Genta’s SPA OK, But Firm Waits For FDA
Agency agrees to special protocol assessment, but Genta will not start trial of Genasense in previously untreated patients until discussions are held on pending application for relapsed/refractory patients.
Agency agrees to special protocol assessment, but Genta will not start trial of Genasense in previously untreated patients until discussions are held on pending application for relapsed/refractory patients.